Wall Street Zen Downgrades Alkermes (NASDAQ:ALKS) to Hold

Alkermes (NASDAQ:ALKS) was downgraded by investment analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a research report issued on Saturday.

Several other brokerages also recently commented on ALKS. Zacks Research downgraded shares of Alkermes from a “strong-buy” rating to a “hold” rating in a research note on Thursday, February 19th. HC Wainwright restated a “neutral” rating and issued a $43.00 price target on shares of Alkermes in a research report on Thursday. Wells Fargo & Company upped their price objective on shares of Alkermes from $37.00 to $43.00 and gave the stock an “overweight” rating in a research note on Thursday. Wolfe Research initiated coverage on shares of Alkermes in a research note on Monday, February 23rd. They issued an “outperform” rating and a $45.00 target price for the company. Finally, Deutsche Bank Aktiengesellschaft decreased their price target on Alkermes from $55.00 to $45.00 and set a “buy” rating on the stock in a research report on Thursday, November 13th. One research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and five have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $44.07.

Alkermes Trading Down 2.1%

ALKS stock opened at $30.10 on Friday. Alkermes has a 1-year low of $25.17 and a 1-year high of $36.32. The business’s 50 day moving average is $31.54 and its 200-day moving average is $30.23. The firm has a market cap of $5.02 billion, a P/E ratio of 21.05, a P/E/G ratio of 7.51 and a beta of 0.53.

Alkermes (NASDAQ:ALKS) last posted its earnings results on Wednesday, February 25th. The company reported $0.29 EPS for the quarter, missing the consensus estimate of $0.43 by ($0.14). Alkermes had a return on equity of 14.91% and a net margin of 16.37%.The company had revenue of $384.55 million for the quarter, compared to the consensus estimate of $380.44 million. During the same quarter last year, the business earned $1.05 EPS. Alkermes’s quarterly revenue was down 10.6% compared to the same quarter last year. Alkermes has set its FY 2026 guidance at -0.798–0.680 EPS. Sell-side analysts forecast that Alkermes will post 1.31 EPS for the current year.

Insider Activity at Alkermes

In other Alkermes news, EVP Craig C. Hopkinson sold 9,000 shares of the company’s stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $33.93, for a total transaction of $305,370.00. Following the transaction, the executive vice president owned 57,740 shares of the company’s stock, valued at approximately $1,959,118.20. This represents a 13.49% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Shane Cooke sold 61,200 shares of Alkermes stock in a transaction on Monday, February 2nd. The shares were sold at an average price of $34.57, for a total value of $2,115,684.00. Following the completion of the sale, the director directly owned 103,744 shares of the company’s stock, valued at $3,586,430.08. This trade represents a 37.10% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 144,148 shares of company stock valued at $4,911,178 in the last 90 days. 4.40% of the stock is currently owned by corporate insiders.

Institutional Trading of Alkermes

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ALKS. Norges Bank bought a new position in shares of Alkermes in the 4th quarter valued at about $54,442,000. Baker BROS. Advisors LP raised its stake in shares of Alkermes by 23.7% during the fourth quarter. Baker BROS. Advisors LP now owns 10,012,267 shares of the company’s stock worth $280,143,000 after buying an additional 1,920,916 shares during the last quarter. UBS Group AG lifted its holdings in Alkermes by 237.4% in the fourth quarter. UBS Group AG now owns 2,544,895 shares of the company’s stock valued at $71,206,000 after buying an additional 1,790,729 shares during the period. JPMorgan Chase & Co. boosted its stake in Alkermes by 32.0% in the fourth quarter. JPMorgan Chase & Co. now owns 5,184,547 shares of the company’s stock valued at $145,064,000 after acquiring an additional 1,256,377 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership boosted its stake in Alkermes by 1,070.6% in the third quarter. Arrowstreet Capital Limited Partnership now owns 1,208,944 shares of the company’s stock valued at $36,268,000 after acquiring an additional 1,105,666 shares during the last quarter. 95.21% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about Alkermes

Here are the key news stories impacting Alkermes this week:

• Positive Sentiment: Analyst optimism — Wells Fargo raised its price target to $43 and kept an overweight stance, signaling bullish analyst conviction that shares have meaningful upside. Wells Fargo raises price target to $43
• Positive Sentiment: RBC still rates ALKS “outperform” and keeps a high price target ($45 after a small cut), indicating continued buy-side support from some sell-side analysts. RBC maintains outperform, lowers PT to $45
• Neutral Sentiment: CEO succession announced — Alkermes disclosed a leadership transition plan; such changes create short-term uncertainty but may be neutral-to-positive over time depending on execution. Alkermes announces CEO succession plan
• Neutral Sentiment: Revenue roughly in line/beat estimates while EPS missed — top-line results were not the primary problem; profitability and EPS dynamics drove the negative reaction. See earnings highlights and call transcript for detail. Q4 2025 earnings highlights
• Negative Sentiment: Earnings miss and downbeat near-term outlook — reported EPS (~$0.29) missed the ~$0.43 consensus and management set FY2026 EPS guidance in negative territory, undercutting the bull case and spurring the sell-off. Shares down after earnings miss
• Negative Sentiment: Market reaction — shares declined sharply on the news and trading volume picked up, reflecting short-term repositioning by investors. Coverage pieces and call transcripts detail investor pushback. ALKS down despite mixed results, leadership change
• Neutral Sentiment: Short-interest reporting in feeds shows inconclusive/zeroed data for February (no actionable signal from that dataset). Short interest note

Alkermes Company Profile

Alkermes plc is a biopharmaceutical company focused on developing innovative medicines to address unmet needs in the central nervous system (CNS). The company applies its proprietary drug delivery technologies and therapeutic expertise to advance treatments for addiction, schizophrenia, bipolar I disorder and depression. Alkermes’ portfolio includes both commercial products and a pipeline of investigational therapies designed to improve patient outcomes and support long-term disease management.

Alkermes’ commercial franchise features several approved products.